Table 1.
Patient characteristics.
| N = 63 | |
|---|---|
| Age (years) | |
| Median (range) | 64 (34–84) |
| Sex | |
| Male | 47 (74.6) |
| Female | 16 (25.4) |
| Ethnicity | |
| Asian | 63 (100.0) |
| Smoking | |
| Never smoked | 21 (33.3) |
| Current or ex-smoker | 42 (66.7) |
| Pathology | |
| Adenocarcinoma | 35 (55.5) |
| Poorly differentiated | 4 (6.3) |
| Sarcomatoid | 3 (4.8) |
| Large cell neuroendocrine | 2 (3.2) |
| Squamous | 19 (30.2) |
| Driver mutation | |
| EGFR | 11 (17.4) |
| KRAS | 2 (3.2) |
| ALK | 1 (1.6) |
| ROS1 | 1 (1.6) |
| Not identified | 48 (76.2) |
| ICI treatment line | |
| 1 | 21 (33.3) |
| 2 | 26 (41.3) |
| ≥ 3 | 16 (25.4) |
| ICI treatment | |
| PD-1 inhibitor | 36 (57.1) |
| PD-L1 inhibitor | 16 (25.4) |
| PD-1 inhibitor + CTLA-4 inhibitor | 5 (7.9) |
| PD-L1 inhibitor + CTLA-4 inhibitor | 5 (7.9) |
| PD-1 inhibitor + chemotherapy | 1 (1.6) |
| PD-L1 expression | |
| ≥ 50% | 18 (28.6) |
| 1–49% | 10 (15.9) |
| 0% | 11 (17.5) |
| Not available | 24 (38.1) |
| Best objective response | |
| Stable disease | 26 (41.3) |
| Partial response | 37 (58.7) |
| Complete response | 0 (0) |
EGFR epidermal growth factor receptor, ALK anaplastic lymphoma kinase, PD-1 programmed death 1, PD-L1 programmed death ligand 1, CTLA-4 Cytotoxic T-Lymphocyte Associated Protein 4.
*Data are presented as the median (range) or number (%).